Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years
Adjuvanted RSVPreF3 was immunologically noninferior in 18-49-year-olds with underlying conditions compared with ≥60-year-olds in whom efficacy was previously demonstrated, supporting efficacy inference in this younger population. Up to 6 months postvaccination, the vaccine elicited robust immune responses, and the safety profile was acceptable. Clinical Trial Registration: NCT06389487.
Authors
- Quentin Deraedt (ORCID: https://orcid.org/0000-0001-9226-2777)
- Roy Rasalam (ORCID: https://orcid.org/0000-0002-6822-7936)
- William Smith (ORCID: https://orcid.org/0000-0003-1569-0799)
- Veronica Hulstrøm
- Silvia Damaso (ORCID: https://orcid.org/0000-0003-4851-4396)
- Céline Verheust
- Marie-Louise Vachon (ORCID: https://orcid.org/0000-0002-2182-8451)
- Agatha Cathrine Wilhase
- Ferdinandus de Looze (ORCID: https://orcid.org/0000-0001-7825-4519)
- Catherine Gérard
- Tino Schwarz
- Judith Hill
- Jonathan Van Gucht
- Helen Stacey
- Dileep Dasyam
- Minoru Nozaki
- Hiwot Amare Hailemariam
- Dominique Descamps
- Murdo Ferguson
Institutions
- The University of Melbourne (AU)
- Shirayuri University (JP)
- Centre hospitalier universitaire de Québec (CA)
- GlaxoSmithKline (Belgium) (BE)
- Alliance for Multispecialty Research (United States) (US)
- Sunshine Hospital (AU)
- Diablo Clinical Research (US)
- Momentum Research (US)
- Centre hospitalier de l'Université Laval (CA)
- GlaxoSmithKline (Switzerland) (CH)
- Stiftung Juliusspital (DE)
- Klinikum Würzburg Mitte (DE)
- Newtown Hospital (GB)
- Colchester School District (US)
- Brigham Young University - Idaho (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1093/cid/ciag058
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00